Pulse Biosciences (Nasdaq : PLSE)

April 2021 Forward-looking statements

This presentation by Pulse Biosciences, Inc., contain estimates and forward-looking statements as of April 26, 2021 including, among others, statements regarding Pulse Biosciences’ future business plans, products, commercial applications, intellectual property strategy, clinical trials, regulatory processes and pathways, and markets for its technologies, as well as patient and physician behavior and preferences and other future events.

You should not place undue reliance on forward-looking statements, as they involve known and unknown risks and uncertainties that are, in some cases, beyond the Company’s control and could cause actual results to differ materially from the information expressed or implied. Factors that could materially affect actual results are described in detail in the Company’s recent Securities and Exchange Commission filings.

Pulse Biosciences undertakes no obligation to revise or update forward-looking statements to reflect future events or circumstances.

® 2 2 Provide superior treatment for a wide range of dermatological conditions through a novel, proprietary, tissue sparing solution

3 3 Novel Bioelectric Medicine Platform

Controlled Addressing FDA 510(k) CE mark Launch unmet need Clearance Approval1 in aesthetic initiated dermatology

Unique Proprietary >$1Bn CellFX immediately utilization CloudConnect available market model with robust IP

1 Health Canada submission pending

® 4 4 Nano-Pulse Stimulation Technology

Non-thermal modality that delivers nanosecond duration pulses of electrical energy

High speed nanosecond energy pulses penetrate the cell membrane and disrupt internal cellular function, leading to regulated cell death

Unlike thermal (heat/cold) technologies, NPS directly impacts cellular structures while sparing non cellular tissue (primarily collagen)

® 5 5 Demonstrated Mechanism of NPS in Skin Safe, precise targeting and elimination of cells while sparing the dermis

Healthy Skin One (1) day post-treatment Seven (7) days post-treatment

• Healthy epidermal cells • Cells in treated epidermis • Healthy epidermis emerges with dark nuclei are nonviable (ghost below cells) • Treated epidermal layer • Cell membranes and peels away surrounding non-cellular

® 6 tissue are intact 6 NPS Technology Delivery Through the CellFX System proprietary platform

Broadly applicable platform with the ability to address multiple treatment targets in commercially significant areas of unmet clinical need

® 7 7 Unmet Need in Aesthetic Dermatology Current treatments lack acceptable cosmetic outcomes or no standard of care exists

Condition Current Standards Aesthetic Sebaceous 60% of patients are Patient Hyperplasia untreated Veterans

• Visit skin specialists for cosmetic procedures several Seborrheic 65% of patients are Keratosis times per year untreated • Seek latest treatment options • Willingness to invest in procedures to look their best 90% of patients receive Warts • Aesthetic procedures are (non-genital) treatment with high generally elective and cash-pay failure rate

® 8 8 Market Opportunity Widespread prevalence among patients visiting aesthetic dermatologists today US1 Europe 2 6,800 Sebaceous Hyperplasia 42 54 Aesthetic Patients per Patients per Physicians week week

Seborrheic Keratosis 84 72 Patients per Patients per >$3B week week Total addressable market Warts (non-genital) 37 55 Patients per Patients per week week

Surveys conducted by third-party market research firm on behalf of Pulse Biosciences, Inc., Full survey results available upon request ® 9 1. Based on 2019 Clinician (n=304) in the U.S. 2. Based on 2020 Clinician (n=46) in Europe 9 Excellent Clinical Data Safety and efficacy across multiple difficult-to-treat dermatologic conditions

SH W SK Cleared SH at 60-day follow-up Cleared Wart at 60-day follow-up Cleared Raised SK at 106-day follow-up

BEFORE AFTER BEFORE AFTER BEFORE AFTER

Sebaceous Hyperplasia Warts (non-genital) Seborrheic Keratosis • 99.5% efficacy rate • Warts achieved complete clearance at • 82% efficacy rate • Clear or mostly clear – 90% a 79% rate, including recalcitrant warts • Clear or mostly clear with with single treatment • 71% of completely cleared warts single treatment • 77% satisfaction rate achieved with 1-2 treatment sessions • 78% satisfaction rate • Previous modalities failed for majority of patients ® 10 10 Strong KOL Support and Advocacy Deep network of leading aesthetic dermatologists Scientific Advisors

CLINICAL PUBLICATIONS 4 ON NPS TECHNOLOGY Dr. Brian Biesman, Nashville, TN Dr. Joel Cohen, Denver, CO Dr. Chris Harmon, Birmingham, AL Dr. Suzanne Kilmer, Sacramento, CA` Dr. Darius Mehregan, Ann Arbor, MI ACCEPTED Dr. Gilly Munavalli, Charlotte, NC PODIUM PRESENTATIONS ABSTRACTS Dr. Tom Rohrer, Chestnut Hill, MA Dr. Vic Ross, San Diego, CA Dr. Elizabeth Tanzi, Chevy Chase, MD 4 12 16 5 Dr. Brian Zelickson, Edina, MN 2018 2019 2020 2021 (Apr/May) Dr. Brian Berman, Aventura, FL Dr. Mark Nestor, Aventura, FL Dr. James Newman, San Mateo, CA Dr. Robert Pierce, Boston, MA ® 11 11 CellFX Controlled Launch A comprehensive and disciplined approach

75 KOL Controlled Launch Clinics KOLs experiences establish best Early adopters will across the U.S. and E.U. practices for implementation of be guided by KOL the CellFX System best practices

Track record for both clinical Shared experiences among peers expertise and commercial at high visibility medical acumen for introducing new conferences and media outlets technologies into a market

® 12 12 Cycles Enable Treatment Delivery Innovative utilization based business model aligns incentives

Patients want to pay based on number of lesions treated

Dermatologists want to treat all patients regardless of condition size/type/amount and want their costs aligned with what they treat

CellFX System is designed to support a business model based on each lesion treated, aligning the patient, physician, and Pulse

® 13 13 CellFX CloudConnect Unique competitive advantage

CloudConnect

Utilization Customer Customer Practice Software/ Data & Management Web Metrics Application Cycle Unit Portal Updates & Management Maintenance

14 14 Practice Economics MD Franchise Based on Expanding Utilization Over Time

Compelling Short-term Economics Long-term Practice Franchise $ $

Initial Three < Four Avg. Ten Avg. Five Lesions Revenue to Investment Patients / Week Month Patients / Week per Patient Practice ~$500,000 / $45,000 Avg. MD Return on • 10 x 15-minute treatment Net MD Rev Year Lesions Revenue Investment session (2.5 hrs) per lesion per Patient per Patient • Benign Lesion, SH, SK, $150-$200 Gross Profit & Warts to Practice 5 lesions / patient $900-$1,200* • Room for growth with ~$400,000 / additional apps Year

® 15 *Average revenue per patient of $1,050 used in ROI calculation yields $63,000 revenue in < four months 15 Extensive CellFX Application Pipeline

EPIDERMAL MID-DERMAL Initial Applications Early Feasibility Work Underway Seborrheic keratosis Sebaceous hyperplasia Future Applications (Raised & Macular) Acne Warts (Pivotal Study) Syringoma DEEP DERMIS / SUBCUTANEOUS Common moles/nevi Intradermal nevi Oily skin Basal Cell Carcinoma Cherry angioma (BCC) Keloid scar Sweat glands Actinic keratosis Melasma Congenital melanocytic nevi Molluscum contagiosum White/blond hair Rhinophyma Subcutaneous fat Xanthelasma Hidradenitis suppurativa Lipomas Sebaceous cysts EPIDERMIS

DERMIS

SUBCUTANEOUS

16 Caution: Applications have not yet been cleared by the FDA 16 CellFX System Regulatory Strategy Expanding indications in US

• Received 510(k) Clearance for general dermatologic indication February 2, 2021 • Stepwise FDA strategy to pursue initial general indication and subsequent specific indications • Completed treatments in FDA IDE approved 60 patient comparative study to generate data for a subsequent 510(k) submission for a specific indication for the treatment of Sebaceous Hyperplasia, submission planned for 1Q21 • Completed initial treatments in FDA IDE comparative study to generate data for a subsequent 510(k) submission for a specific indication for the treatment of common non-genital warts • CE mark approval received January 22, 2021 • Health Canada Medical Device License application under review ® 17 17 Upcoming Milestones • Controlled launch system implementations throughout Q1, Q2 and Q3 of 2021 • Regulatory Steps for the CellFX System • Subsequent 510(k) submission for SH indication planned for 1Q21 • Potential receipt of Health Canada Medical Device License as early as 2Q21 • Progress Clinical and Scientific programs • Continued presence at scientific meetings • Continue to Expand Pipeline of Clinical Applications

18 18 As of January 2021 Robust IP Portfolio 112 issued Multipronged Patent Strategy patents • Pioneering IP for the use of nanosecond pulses in biology

globally • Covering methods and tools for the application of nanosecond owned pulses in biology • Pioneering IP and continued development of IP with focus on & licensed skin-based applications

Additional 96 patent applications pending • Continued development and patent filings covering systems, worldwide applications, and methods of combining nanosecond pulsing with other biological technologies and agents

19 19 Cash Utilization Financial Snapshot

2019 $34.2MM December 31, 2020 2020 $34.6MM (In thousands) Cash, cash equivalents & investments $ 20,475 • As of 12/31/20 cash, cash equivalents Prepaids & other assets 2,229 and investments were $20.5MM Property, plant and equipment 2,478 • Closed over-oversubscribed Rights Goodwill & intangibles 6,673 Offering in June 2020 with $29.5MM in Right of use assets 9,438 net proceeds Total assets $ 41,293 • Exercise of warrants issued in Rights Offering generated gross proceeds of Accounts payable & accrued liabilities $ 7,043 $4.5MM, not reflected in 12/31/20 cash Lease liability 11,356 balance Debt -- • February 2021 At-the-Market Equity Stockholders' equity 22,894 Offering of up to $60MM Total liabilities & stockholders' equity $ 41,293 • No debt Shares outstanding (as of 2/9/2021) 26,062

® 20 20 Leadership Team Proven and experienced in growing medical technology from clinical to commercial stage

Management Darrin Uecker President & Chief Executive Officer

Edward Ebbers EVP & GM, Dermatology Sandra Gardiner EVP & Chief Financial Officer

Board of Directors

Bob Duggan, Chairman Maky Zanganeh, D.D.S. Mitch Levinson

Richard van den Broek Kenneth Clark Manmeet Soni

HSMR Advisors

21 ® 21 Thank You

CONFIDENTIAL - FOR INTERNAL USE ONLY 22